Condition: Head and Neck Squamous Cell Carcinoma · Sponsor: Yuankai Shi
This trial is main evaluate the efficacy and safety of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma
This description comes directly from the study's public registry record.
Yuankai Shi, MD · +86-10-87788293 · syuankaipumc@126.com
Always discuss trial participation with your own doctor first.
| National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04857164